These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1145 related items for PubMed ID: 10416608

  • 1. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, Sehested M.
    Cancer Res; 1999 Jul 15; 59(14):3442-50. PubMed ID: 10416608
    [Abstract] [Full Text] [Related]

  • 2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 3. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M.
    BMC Pharmacol; 2004 Dec 02; 4():31. PubMed ID: 15575955
    [Abstract] [Full Text] [Related]

  • 4. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb 02; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 5. Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha.
    Wessel I, Jensen LH, Renodon-Corniere A, Sorensen TK, Nitiss JL, Jensen PB, Sehested M.
    FEBS Lett; 2002 Jun 05; 520(1-3):161-6. PubMed ID: 12044890
    [Abstract] [Full Text] [Related]

  • 6. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T.
    Cancer Res; 1995 Jun 01; 55(11):2299-303. PubMed ID: 7757979
    [Abstract] [Full Text] [Related]

  • 7. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
    Sorensen M, Sehested M, Jensen PB.
    Mol Pharmacol; 1999 Mar 01; 55(3):424-31. PubMed ID: 10051525
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
    Renodon-Cornière A, Jensen LH, Nitiss JL, Jensen PB, Sehested M.
    Biochemistry; 2003 Aug 19; 42(32):9749-54. PubMed ID: 12911317
    [Abstract] [Full Text] [Related]

  • 12. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M, Jensen PB.
    Biochem Pharmacol; 1996 Apr 12; 51(7):879-86. PubMed ID: 8651936
    [Abstract] [Full Text] [Related]

  • 13. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L, Hansen HF, Wessel I, Nitiss JL, Schmidt G, Jensen PB, Sehested M, Jensen LH.
    Anticancer Drug Des; 2001 Dec 12; 16(6):305-15. PubMed ID: 12375883
    [Abstract] [Full Text] [Related]

  • 14. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
    Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT.
    Cancer Res; 1993 Mar 15; 53(6):1373-9. PubMed ID: 8383009
    [Abstract] [Full Text] [Related]

  • 15. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 16. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF.
    Biochemistry; 1999 Aug 17; 38(33):10793-800. PubMed ID: 10451375
    [Abstract] [Full Text] [Related]

  • 17. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
    Samata K, Yamagishi T, Ichihara T, Nanaumi K, Ikeda T, Ikeya H, Kuraishi A, Nakaike S, Kashiwagi K, Igarashi K.
    Cancer Chemother Pharmacol; 2002 Nov 17; 50(5):367-72. PubMed ID: 12439594
    [Abstract] [Full Text] [Related]

  • 18. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR, Foster SR, Maxwell A.
    J Mol Biol; 2000 Jul 14; 300(3):481-91. PubMed ID: 10884345
    [Abstract] [Full Text] [Related]

  • 19. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy.
    Karnaoukhova L, Moffat J, Martins H, Glickman B.
    Cancer Res; 1997 Oct 01; 57(19):4393-407. PubMed ID: 9331103
    [Abstract] [Full Text] [Related]

  • 20. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R.
    Oncol Res; 1996 Oct 01; 8(6):229-38. PubMed ID: 8895198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.